Indogulf Cropsciences Q2 FY27: EBITDA Surges 27% to ₹41 Cr, PAT Up 24% to ₹26 Cr.
Indogulf Cropsciences reported strong Q2 FY27 results with Total Income at ₹256 Cr (up 3% YoY). EBITDA surged 27% YoY to ₹41 Cr, and PAT grew 24% YoY to ₹26 Cr. EBITDA margin expanded by 300 bps to 16%. H1 FY27 saw EBITDA up 20% YoY to ₹50 Cr and PAT up 14% YoY to ₹28 Cr.
The strong financial results, including substantial growth in key profitability metrics and margin expansion, are likely to have a significant positive impact on investor sentiment and the company's stock.
The company reported significant year-on-year growth in EBITDA and PAT, along with margin expansion, indicating a positive financial performance.
Indogulf Cropsciences Limited announced its consolidated unaudited financial results for the quarter and half year ended September 30, 2026. For the second quarter of Fiscal Year 2027 (Q2 FY27), the company reported a Total Income of ₹256 crore, a 3% year-on-year (YoY) growth, despite challenging monsoon conditions. Revenue increased by a notable 52% quarter-on-quarter (QoQ). EBITDA saw a significant 27% YoY increase to ₹41 crore, with the EBITDA margin expanding by 300 basis points to 16%. Profit After Tax (PAT) grew by 24% YoY to ₹26 crore, with the PAT margin improving to 10%.<br><br>For the first half of Fiscal Year 2027 (H1 FY27), Total Income stood at ₹424 crore, a marginal 3% YoY decline. However, gross profit increased by 7% YoY to ₹123 crore, with gross margin improving to 29%. EBITDA for H1 FY27 grew by 20% YoY to ₹50 crore, and the EBITDA margin expanded to 12%. PAT for H1 FY27 increased by 14% YoY to ₹28 crore, with PAT margin improving to 7%.<br><br>Commenting on the performance, Managing Director Mr. Sanjay Aggarwal highlighted the strong EBITDA and PAT growth driven by a favorable product mix and disciplined execution. He also mentioned his recent honor of receiving the 17th Visionary Leadership Award 2026. Mr. Aggarwal expressed optimism about the future, citing opportunities in Indian agriculture, growing adoption of modern crop solutions, and export potential. The company plans to strengthen its biologicals and plant nutrients portfolio, enhance manufacturing capabilities, and expand its international presence.
What to do with a filing like this
Indogulf Cropsciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indogulf Cropsciences Limited. Read the original for the full detail.